A detailed history of First Horizon Advisors, Inc. transactions in Myriad Genetics Inc stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 38 shares of MYGN stock, worth $513. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38
Holding current value
$513
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$23.97 - $28.6 $910 - $1,086
38 New
38 $1,000
Q3 2022

Nov 09, 2022

SELL
$18.21 - $27.88 $36,693 - $56,178
-2,015 Reduced 63.17%
1,175 $22,000
Q2 2022

Aug 02, 2022

BUY
$16.45 - $25.88 $52,475 - $82,557
3,190 New
3,190 $57,000
Q4 2021

Feb 09, 2022

SELL
$24.13 - $32.63 $651 - $881
-27 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$29.97 - $36.66 $719 - $879
-24 Reduced 47.06%
27 $0
Q3 2021

Nov 09, 2021

BUY
$29.97 - $36.66 $1,528 - $1,869
51 New
51 $1,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.09B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.